Regenxbio Inc. (RGNX) Sets New 12-Month Low at $7.67
Regenxbio Inc. (NASDAQ:RGNX)’s share price reached a new 52-week low on Wednesday . The company traded as low as $7.67 and last traded at $7.86, with a volume of 204,052 shares. The stock had previously closed at $7.87.
A number of equities analysts have weighed in on the stock. Zacks Investment Research cut shares of Regenxbio from a “buy” rating to a “hold” rating in a research report on Thursday. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $33.00 target price on shares of Regenxbio in a report on Tuesday. Chardan Capital reaffirmed a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Finally, Morgan Stanley upped their target price on shares of Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $28.35.
The stock’s 50 day moving average price is $10.61 and its 200 day moving average price is $12.16. The stock’s market capitalization is $210.44 million.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. On average, equities research analysts expect that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.
In other Regenxbio news, insider Fmr Llc sold 18,300 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $12.41, for a total value of $227,103.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.